EGFR and central nervous system cancer: Notably, neocortical gliomas are more aggressive, with higher Ki67 indices and Telomerase Reverse Transcriptase (TERT) promoter mutation rates, compared to mesocortical gliomas, which exhibit longer survival and distinct molecular alterations, including lower Epidermal Growth Factor Receptor (EGFR) amplification and a higher prevalence of 1p/19q co-deletion [4].